1. Home
  2. Clinical Topics
  3. FDA announces new risk factor for PML associated with Tysabri
Clinical TopicsDrugs and DevicesInfection PreventionNeurologyWeb Exclusives

FDA announces new risk factor for PML associated with Tysabri

Share

On Jan. 20, the U.S. Food and Drug Administration (FDA) announced that testing positive for anti-JC virus antibodies has been identified as a risk factor for progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection associated with use of Tysabri (natalizumab) for the treatment of multiple sclerosis or Crohn’s disease. Read more.

Leave a Reply

Your email address will not be published.

Fill out this field
Fill out this field
Please enter a valid email address.

Get your free subscription to NurseLine!

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Recent Posts